TREA

97618584 - FORTITUDE

Follow

Information

  • Trademark
  • 97618584
  • Serial Number
    97618584
  • Filing Date
    October 04, 2022
    2 years ago
  • Transaction Date
    May 17, 2024
    7 months ago
  • Status Date
    May 17, 2024
    7 months ago
  • Location Date
    May 17, 2024
    7 months ago
  • Status Code
    602
  • Current Location
    TMEG LAW OFFICE 104 - EXAMINING ATTORNEY ASSIGNED
    Employee Name
    ROCCA, ALAINA M
  • Attorney Docket Number
    45532-TM1012
    Attorney Name
    Aaron D. Hendelman
    Law Office Assigned Location Code
    L40
  • Owners
Information
Mark Drawing Code
4
Mark Identification
FORTITUDE
Case File Statements
  • GS0051: Therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; all of the foregoing excluding diagnostic preparations, reagents, and products
  • GS0421: Scientific research in the nature of conducting clinical trials for others in the fields of pharmaceuticals and biotechnology, namely, conducting clinical trials for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and biotechnology; medical and scientific research, namely, conducting clinical trials for others for oligonucleotide-based therapeutics; all of the foregoing excluding medical and scientific research related to diagnostic preparations, reagents, and products
Case File Event Statements
  • 7/13/2023 - a year ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 10/7/2022 - 2 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 10/7/2022 - 2 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 6/28/2023 - a year ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 7/13/2023 - a year ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 7/13/2023 - a year ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 10/6/2023 - a year ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 10/6/2023 - a year ago
    8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 10/7/2023 - a year ago
    9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 2/1/2024 - 11 months ago
    10 - FINAL REFUSAL WRITTEN Type: CNFR
  • 2/1/2024 - 11 months ago
    11 - FINAL REFUSAL E-MAILED Type: GNFR
  • 2/1/2024 - 11 months ago
    12 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 5/17/2024 - 7 months ago
    13 - ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Type: ABN2
  • 5/17/2024 - 7 months ago
    14 - ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Type: MAB2